Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,
An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that
Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is und
EQRx's pledge to disrupt the pharma pricing system started with a clarion call in 2020 but ended with a whimper today with an agreement to be taken over by Revolution Medi
Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.